Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropren in Acute Coronary Syndrome
NCT03122340Phase 3Completed
- Sponsor
- Tomsk National Research Medical Centre of the Russian Academy of Sciences
- Start
- Nov 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute coronary syndrome (ACS) comparing Polyprenol Group with Placebo Group (2 arms). Primary endpoints: Cardiospecific enzymes at 9 days, Hepatic enzymes at 2 months and 5 more. Started Nov 2015; status: completed.
02
Drugs
Ropren
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT03122340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03122340.